PROX1 Antibody

What is PROX1 and what biological systems is it primarily involved in?

PROX1 is a homeobox-containing transcription factor that functions as a key regulatory protein in multiple developmental processes. It plays critical roles in neurogenesis and the development of various organs including the heart, eye lens, liver, pancreas, and lymphatic system. Additionally, PROX1 is involved in circadian rhythm regulation, acting as a repressor of retinoid-related orphan receptor RORG and affecting the expression of core clock components like BMAL1, NPAS2, and CRY1 .

At the molecular level, PROX1 influences cell fate determination, gene transcriptional regulation, and progenitor cell regulation. Its expression is tightly regulated during embryonic development and remains important in adult tissues for maintaining proper cellular function and identity.

What are the most reliable applications for PROX1 antibodies in research settings?

PROX1 antibodies have demonstrated reliability across multiple research applications:

• Western Blot Analysis: PROX1 antibodies can detect specific bands at approximately 83-114 kDa in human cell lysates, particularly in HepG2 hepatocellular carcinoma cells . The variance in observed molecular weight may depend on experimental conditions and post-translational modifications.

• Immunocytochemistry/Immunofluorescence (ICC/IF): PROX1 antibodies effectively localize the protein primarily in the nucleus, with particularly strong staining in fixed cells. For example, in HepG2 cells, PROX1 shows clear nuclear localization when detected with appropriate antibodies and visualization systems .

• Immunohistochemistry (IHC): PROX1 antibodies work well in paraformaldehyde-fixed, paraffin-embedded tissues, allowing for examination of PROX1 expression patterns in developmental studies and disease models .

• Simple Western™ Analysis: This automated capillary-based size separation technique has been validated for PROX1 detection using specific antibodies .

How do I determine the appropriate PROX1 antibody for my specific experimental needs?

Selection of the appropriate PROX1 antibody requires careful consideration of several factors:

• Species Reactivity: Ensure the antibody recognizes PROX1 in your species of interest. For example, anti-PROX1 antibody [EPR19273] reacts with human, mouse, and rat samples , while other antibodies may have different species specificities.

• Application Compatibility: Verify that the antibody has been validated for your intended application. For instance, the AF2727 antibody has been validated for Western blot, ICC/IF, and Simple Western applications .

• Epitope Recognition: Consider which domain of PROX1 the antibody recognizes. Antibodies targeting different epitopes may yield different results based on protein conformation or interaction status.

• Clonality: Monoclonal antibodies like EPR19273 offer high specificity and reproducibility for precise detection , while polyclonal antibodies may provide stronger signals by recognizing multiple epitopes.

• Validation Data: Review scientific literature and manufacturer validation data showing the antibody's performance in applications and models similar to your experimental system.

A detailed comparison table of common commercially available PROX1 antibodies would include:

What are the optimal conditions for Western blot detection of PROX1?

Optimal Western blot conditions for PROX1 detection require attention to several technical parameters:

• Sample Preparation: Lyse cells in RIPA buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1% Nonidet P-40, 0.1% sodium dodecyl sulfate [SDS], and 0.5% sodium deoxycholate) supplemented with protease and phosphatase inhibitors .

• Protein Loading: Load approximately 20 μg of protein per lane for cell lysates. For HepG2 cells, which express PROX1 at detectable levels, this amount is typically sufficient .

• Gel Percentage: Use 10% SDS-polyacrylamide gels for optimal separation of PROX1 (MW ~83 kDa) .

• Transfer Conditions: Transfer to PVDF membranes is recommended over nitrocellulose for higher protein retention .

• Antibody Concentration: For AF2727 antibody, a concentration of 1 μg/mL has been validated for Western blot detection . For Simple Western analysis, a higher concentration (10 μg/mL) may be necessary .

• Detection System: HRP-conjugated secondary antibodies followed by enhanced chemiluminescence provide robust detection. For AF2727, use anti-goat IgG secondary antibodies (e.g., HAF019 at manufacturer-recommended dilutions) .

• Reducing Conditions: PROX1 detection is typically performed under reducing conditions to ensure proper denaturation and epitope exposure .

What are the critical parameters for successful immunofluorescence detection of PROX1?

Successful immunofluorescence detection of PROX1 requires attention to the following parameters:

• Fixation Method: 4% paraformaldehyde fixation for 20 minutes at room temperature yields good results while preserving cellular structure .

• Permeabilization: Use 0.2% Triton X-100 in PBS to allow antibody access to nuclear PROX1 .

• Antibody Concentration: For the AF2727 antibody, a concentration of 15 μg/mL applied for 3 hours at room temperature has been successfully used . Other antibodies may require different concentrations and incubation times.

• Secondary Antibody Selection: Choose a fluorophore-conjugated secondary antibody appropriate for your imaging system. NorthernLights™ 557-conjugated anti-goat IgG has been validated for PROX1 detection when using the AF2727 primary antibody .

• Counterstaining: DAPI nuclear counterstaining helps visualize the nuclear localization of PROX1 and provides context for cell morphology .

• Control Samples: Include secondary-only controls to evaluate background fluorescence and positive control cell lines (e.g., HepG2) to confirm staining patterns .

• Blocking Solution: Use an appropriate blocking solution (typically 5-10% normal serum from the species of the secondary antibody) to minimize non-specific binding.

Why might I observe different molecular weights for PROX1 in Western blot analysis?

The observation of different molecular weights for PROX1 in Western blot analysis can be attributed to several factors:

• Post-translational Modifications: PROX1 undergoes various post-translational modifications that can alter its electrophoretic mobility. Phosphorylation, in particular, can increase the apparent molecular weight.

• Protein Isoforms: Alternative splicing may generate different PROX1 isoforms with varying molecular weights.

• Experimental Conditions: The predicted molecular weight of PROX1 is 83 kDa , but detection at approximately 114 kDa has been reported in Simple Western analysis . This discrepancy may result from differences in gel systems, running buffers, or reduction conditions.

• Protein-Protein Interactions: Incomplete denaturation may result in PROX1 remaining in complex with interacting proteins, leading to higher molecular weight bands.

• Degradation Products: Lower molecular weight bands may represent proteolytic fragments of PROX1, particularly if samples are not properly handled or if protease inhibitors are insufficient.

To address these variations, researchers should:

• Include molecular weight markers in all blots

• Use positive control lysates (e.g., HepG2 cells) to establish expected band patterns

• Verify antibody specificity through knockdown or overexpression experiments

• Document running conditions thoroughly for reproducibility

How can I validate the specificity of my PROX1 antibody?

Validating PROX1 antibody specificity is critical for ensuring reliable research outcomes. Multiple approaches should be combined:

• Genetic Manipulation:

  • Knockdown: Use siRNA targeting PROX1 (e.g., 5′-GCAAAGAUGUUGAUCCUUCTT-3′ and 5′-GAAGGAUCAACAUCU-UUGCTT-3′) to reduce expression and confirm corresponding reduction in antibody signal .

  • Overexpression: Transfect cells with PROX1 expression constructs (e.g., human PROX1 coding sequence in pcDNA3) and verify increased antibody signal .

• Multiple Antibodies: Use antibodies from different sources or those targeting different epitopes of PROX1 to confirm consistent detection patterns.

• Positive and Negative Controls:

  • Positive controls: HepG2 cells show high PROX1 expression and serve as excellent positive controls .

  • Tissue controls: Lymphatic endothelial cells, hippocampal neurons, and developing lens tissue express PROX1 and can serve as positive controls in tissue sections .

  • Negative controls: Include secondary antibody-only controls to assess background staining .

• Immunoprecipitation Followed by Mass Spectrometry: This approach can confirm that the antibody is specifically pulling down PROX1 protein.

• Peptide Competition Assay: Pre-incubation of the antibody with a synthetic peptide matching the epitope should abolish specific staining if the antibody is truly specific.

What experimental models are most suitable for studying PROX1 function?

Several experimental models are particularly valuable for investigating PROX1 function:

• Cell Line Models:

  • HepG2 hepatocellular carcinoma cells express high levels of PROX1 and are well-characterized for PROX1 studies .

  • Lymphatic endothelial cells (LECs) express PROX1 as a lineage-specific marker and are ideal for studying its role in lymphatic development .

  • C2C12 myoblasts show regulated PROX1 expression during differentiation, making them useful for studying PROX1's role in muscle development .

• Primary Cell Models:

  • Primary human myoblasts exhibit PROX1 expression changes during differentiation .

  • Primary lymphatic endothelial cells (HLECs) express PROX1 and can be manipulated to study its function .

• In Vivo Models:

  • Xenograft models using cells with manipulated PROX1 expression can reveal its role in tumor growth .

  • Tissue-specific knockout or transgenic mouse models targeting PROX1 in specific organs provide insights into developmental roles.

• Organoid Models:

  • Liver, pancreatic, or lymphatic organoids can recapitulate developmental processes regulated by PROX1 in a more physiologically relevant context than monolayer cultures.

The choice of model should align with the specific biological question being addressed about PROX1 function in development, differentiation, or disease contexts.

How can I effectively knockdown or overexpress PROX1 for functional studies?

For effective manipulation of PROX1 expression in functional studies:

PROX1 Knockdown Strategies:

• siRNA Transfection:

  • Validated siRNA sequences: 5′-GCAAAGAUGUUGAUCCUUCTT-3′ and 5′-GAAGGAUCAACAUCU-UUGCTT-3′ .

  • Transfection reagent: Lipofactor-2000 has been successfully used for PROX1 siRNA delivery .

  • Validation: Confirm knockdown efficiency by Western blot or qRT-PCR at 48-72 hours post-transfection.

• shRNA Approaches:

  • Lentiviral shRNA delivery provides stable knockdown for long-term studies.

  • Co-expression of GFP markers facilitates identification of transduced cells .

• CRISPR/Cas9 Gene Editing:

  • Complete knockout can be achieved using CRISPR/Cas9 technology as demonstrated in HLEC lines .

  • Verify knockout by Western blot and functional assays.

PROX1 Overexpression Strategies:

Important Considerations:

• Control for transfection effects using scrambled siRNA or empty vector controls.

• Verify expression changes at both mRNA and protein levels.

• Consider the stability of PROX1 protein (can be assessed with cycloheximide chase experiments) .

• Assess functional outcomes relevant to the known roles of PROX1 in your model system.

How does PROX1 interact with the mTOR pathway in cellular growth regulation?

PROX1 has been identified as a key mediator of the anti-proliferative effect of rapamycin, indicating an important intersection between PROX1 and the mTOR (mechanistic target of rapamycin) signaling pathway :

• Rapamycin Effects on PROX1:

  • Treatment with rapamycin (10 nM) increases PROX1 expression in vitro, suggesting that mTOR activity normally suppresses PROX1 levels .

  • This regulation occurs at both transcriptional and post-translational levels, with evidence suggesting that mTOR inhibition increases PROX1 protein stability.

• Functional Significance:

  • PROX1 upregulation appears to be a critical mediator of rapamycin's anti-proliferative effects.

  • When PROX1 is knocked down using siRNA, the growth-inhibitory effects of rapamycin are significantly attenuated .

• In Vivo Evidence:

  • Xenograft models treated with rapamycin (4 mg/kg) show increased PROX1 expression in tumor tissues, correlating with reduced tumor growth .

  • This effect is observed both when rapamycin is administered before tumor formation and after tumors have already developed to a significant size.

• Mechanistic Insights:

  • PROX1 may act as a transcriptional regulator of cell cycle-related genes downstream of mTOR signaling.

  • The increased PROX1 following mTOR inhibition appears to be a useful marker for assessing rapamycin sensitivity in cellular and tissue models.

This interaction suggests potential applications in cancer therapeutics where modulating PROX1 levels might enhance the efficacy of mTOR inhibitors or overcome resistance mechanisms.

What is the role of PROX1 in lymphatic endothelial cell biology and development?

PROX1 serves as a master regulator of lymphatic endothelial cell (LEC) identity and function:

• Lineage Determination:

  • PROX1 is a key determinant of LEC fate specification from venous endothelial cells during development.

  • Its expression marks lymphatic commitment and is maintained in mature LECs throughout adult life.

• LEC Subpopulation Heterogeneity:

  • Research has identified distinct LEC subpopulations with varying PROX1 expression profiles .

  • In human lymph nodes, PROX1-positive LECs show differential co-expression with markers such as LYVE-1, CD36, MARCO, and CLEC4M, indicating functional specialization .

• Regulatory Networks:

  • GATA2 appears to function upstream of PROX1 in the transcriptional network governing LEC biology.

  • GATA2 knockout in human LECs (HLECs) using CRISPR/Cas9 does not significantly alter PROX1 expression, suggesting parallel or complementary regulatory pathways .

  • RNA-seq analysis of GATA2-depleted HLECs identifies downstream genes that may interact with PROX1-regulated pathways .

• Functional Implications:

  • PROX1-positive LECs in lymph nodes include CD36-high LYVE-1-positive paracortical sinuses (Ptx3-LECs) .

  • These specialized LECs are associated with MARCO-positive CLEC4M-positive Marco-LECs, suggesting functional interaction between these subpopulations .

• Technical Identification:

  • Immunofluorescence co-staining for PROX1 with CD36, LYVE-1, MARCO, and CLEC4M enables identification of LEC subpopulations in tissue sections .

  • Scale bars of 100-500 μm are appropriate for visualizing these structures in human lymph nodes .

Understanding PROX1's role in lymphatic biology has implications for lymphedema, inflammation, and cancer metastasis research, as lymphatic vessels serve as conduits for immune cell trafficking and tumor dissemination.

How does PROX1 influence muscle development and myoblast differentiation?

PROX1 plays a significant regulatory role in muscle development and myoblast differentiation:

• Expression Dynamics During Differentiation:

  • In C2C12 mouse myoblasts, both PROX1 mRNA and protein levels change during differentiation, correlating with changes in MyoD1 expression, a key myogenic transcription factor .

  • Similar expression patterns are observed in primary human myoblasts before and after differentiation, suggesting a conserved role across species .

• Functional Significance:

  • PROX1 silencing in myoblasts has profound effects on proliferation and differentiation-related gene expression.

  • In human myoblasts, PROX1 knockdown alters the expression of CyclinD1, Myf5, and MyoD before and after differentiation .

  • In C2C12 cells, PROX1 silencing completely blocks myotube development, with only occasional cells expressing myosin, and these cells are negative for the shProx1-GFP marker .

• Methodological Approaches:

  • Lentiviral shRNA delivery with GFP co-expression enables tracking of PROX1-depleted cells during differentiation .

  • Myosin staining serves as a terminal differentiation marker to assess myogenic progression .

  • Quantitative analysis typically involves measuring transcript levels of myogenic markers (MyoD, Myf5) and cell cycle regulators (CyclinD1) .

• Quantitative Assessment:

  • Statistical analysis using one-way ANOVA with repeated measures followed by Tukey's post-hoc test and Student's two-tailed unpaired t-test provides robust evaluation of PROX1's effects .

  • Experiments typically involve three biological replicates repeated three times to ensure reproducibility .

These findings highlight PROX1 as a potential therapeutic target in conditions involving abnormal muscle regeneration or muscular dystrophies where myoblast differentiation is dysregulated.

What are common issues when detecting PROX1 via Western blot and how can they be resolved?

Researchers frequently encounter several challenges when detecting PROX1 by Western blot. Here are common issues and their solutions:

• Inconsistent Molecular Weight:

  • Issue: PROX1 may appear at different molecular weights (83 kDa vs. 114 kDa) depending on experimental conditions .

  • Solution: Include positive control lysates (e.g., HepG2) in each experiment to establish expected migration patterns. Use consistent gel percentages (10% recommended) and running conditions to maintain reproducibility .

• Weak Signal:

  • Issue: Insufficient signal intensity makes PROX1 detection difficult.

  • Solution: Optimize protein loading (20-30 μg recommended), increase antibody concentration (up to 1-2 μg/mL for most PROX1 antibodies), extend primary antibody incubation (overnight at 4°C), and use high-sensitivity ECL detection systems .

• Multiple Bands:

  • Issue: Detection of multiple bands creating uncertainty about specific PROX1 signal.

  • Solution: Validate specific bands using positive controls, PROX1 knockdown/overexpression controls, and longer blocking times (1-2 hours) with 5% non-fat dry milk or BSA to reduce non-specific binding .

• High Background:

  • Issue: Excessive background obscuring specific PROX1 signal.

  • Solution: Increase washing steps (at least 3 x 10 minutes with TBST), reduce secondary antibody concentration, consider using different blocking agents (switch between milk and BSA), and ensure membranes are fully submerged during all incubation steps.

• Protein Degradation:

  • Issue: Degradation bands appearing below the expected PROX1 band.

  • Solution: Use fresh protease inhibitor cocktails in lysis buffers, maintain samples at 4°C during processing, avoid repeated freeze-thaw cycles, and reduce sample heating time prior to loading (5 minutes at 95°C is typically sufficient) .

• Transfer Efficiency:

  • Issue: Poor transfer of high molecular weight proteins.

  • Solution: Use PVDF membranes for higher protein retention, extend transfer time, reduce methanol concentration in transfer buffer for high molecular weight proteins, and consider semi-dry vs. wet transfer systems based on protein size .

How can I optimize immunohistochemical detection of PROX1 in tissue sections?

Optimizing PROX1 detection in tissue sections requires attention to several critical parameters:

• Fixation Optimization:

  • Issue: Overfixation may mask epitopes while underfixation can compromise tissue morphology.

  • Solution: For formalin-fixed paraffin-embedded (FFPE) tissues, limit fixation to 24 hours in 4% paraformaldehyde. For frozen sections, brief fixation (10-20 minutes) in 4% paraformaldehyde generally preserves both antigenicity and morphology .

• Antigen Retrieval Methods:

  • Issue: Formalin fixation creates protein cross-links that mask antigens.

  • Solution: Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) is effective for most PROX1 antibodies. Optimize heating time (typically 15-20 minutes) and cooling period (20 minutes at room temperature) .

• Antibody Dilution and Incubation:

  • Issue: Suboptimal antibody concentration leads to weak signal or high background.

  • Solution: Titrate primary antibody concentrations (typical working dilutions range from 1:300 to 1:500 for commercial PROX1 antibodies). Extend incubation times (overnight at 4°C) for weaker antibodies .

• Detection Systems:

  • Issue: Insufficient sensitivity for low-abundance PROX1.

  • Solution: Use polymer-based detection systems or tyramide signal amplification (TSA) for enhanced sensitivity. For immunofluorescence, bright fluorophores (Alexa Fluor series) and appropriate filters minimize bleed-through and maximize signal detection .

• Signal Quantification:

  • Issue: Difficulty in objectively quantifying PROX1 expression levels.

  • Solution: Use image analysis software (e.g., ImageJ) to quantify the number of positive pixels per tumor/tissue area. Report results as mean numbers of positive pixels/tissue area for reproducible assessment .

• Multi-color Analysis:

  • Issue: Difficulty distinguishing PROX1-positive cell populations in heterogeneous tissues.

  • Solution: Implement multi-color immunofluorescence with markers like CD36, LYVE-1, MARCO, or CLEC4M to identify specific PROX1-expressing cell populations. Use sequential rather than cocktail antibody application to minimize cross-reactivity .

• Controls:

  • Issue: Uncertainty about staining specificity.

  • Solution: Include tissue-specific positive controls (lymphatic vessels, hippocampal neurons), negative controls (secondary antibody only), and isotype controls to verify specificity in each staining batch .

How is PROX1 involved in cancer biology, and what are the implications for targeted therapies?

PROX1's role in cancer biology is complex and context-dependent, with significant implications for therapeutic development:

• PROX1 in Hepatocellular Carcinoma (HCC):

  • PROX1 is expressed in HepG2 hepatocellular carcinoma cells, where it can be detected by various antibodies and analytical methods .

  • Its expression in liver cancer may reflect its normal role in hepatocyte differentiation and liver development.

  • The potential therapeutic relevance is highlighted by studies showing that rapamycin-induced PROX1 upregulation correlates with decreased tumor growth in xenograft models .

• Mechanistic Insights from mTOR Pathway Interaction:

  • PROX1 upregulation appears to be a key mediator of the anti-proliferative effects of rapamycin .

  • This suggests that PROX1 expression levels might serve as a biomarker for predicting sensitivity to mTOR inhibitors in cancer therapy.

  • Targeting PROX1 expression or activity could potentially enhance the efficacy of existing mTOR inhibitors or overcome resistance mechanisms.

• Research Approaches:

  • In Vitro Models: Cell lines with manipulated PROX1 expression can be treated with various therapeutic agents to assess synergistic effects .

  • In Vivo Xenograft Models: Subcutaneous inoculation of cancer cells with altered PROX1 expression (100 μL at 2×108/mL concentration) provides a platform for testing therapeutic interventions .

  • Treatment Protocols: Daily administration of rapamycin (4 mg/kg, i.p.) for 14 days has been validated for studying PROX1-mediated effects in vivo .

  • Analysis Methods: Tumor volume measurement (V = L × W2/2), histological examination (H&E staining), and immunohistochemical analysis of PROX1 expression provide comprehensive assessment of therapeutic outcomes .

• Future Research Directions:

  • Developing small molecule modulators of PROX1 activity could offer new therapeutic avenues.

  • Exploring combinatorial approaches with existing cancer therapies may reveal synergistic effects.

  • Investigating PROX1's role in cancer stem cell maintenance and therapy resistance represents an emerging area of interest.

What technological advances are enhancing our ability to study PROX1 in complex biological systems?

Recent technological developments have significantly advanced our capability to study PROX1 in diverse biological contexts:

• Advanced Imaging Techniques:

  • Multiplexed Immunofluorescence: Simultaneous detection of PROX1 with multiple markers (CD36, LYVE-1, MARCO, CLEC4M) enables identification of specialized cell populations and their spatial relationships in tissues .

  • Super-Resolution Microscopy: Techniques like STED or STORM provide nanoscale resolution of PROX1 localization and co-localization with interaction partners within the nucleus.

• Genomic and Transcriptomic Approaches:

  • RNA-seq Analysis: This technology has been used to identify downstream targets of transcription factors like GATA2 that may interact with PROX1-regulated pathways in lymphatic endothelial cells .

  • Single-Cell RNA-seq: This approach can reveal heterogeneity in PROX1 expression and associated gene networks across individual cells within a population.

  • ChIP-seq: Chromatin immunoprecipitation followed by sequencing can identify genome-wide PROX1 binding sites to elucidate its direct transcriptional targets.

• Gene Editing Technologies:

  • CRISPR/Cas9 System: This has been successfully employed to generate GATA2 knockout lymphatic endothelial cells, providing insights into regulatory networks involving PROX1 .

  • Inducible Gene Expression/Knockout Systems: Temporal control of PROX1 expression enables studies of its role at specific developmental stages or in disease progression.

• Protein Analysis Methods:

  • Simple Western™: This automated capillary-based size separation technique offers improved reproducibility for PROX1 protein quantification compared to traditional Western blotting .

  • Proximity Ligation Assays (PLA): These can detect and visualize protein-protein interactions involving PROX1 in situ with high sensitivity and specificity.

• In Vitro Model Systems:

  • Organoids: Three-dimensional culture systems recapitulating organ development provide physiologically relevant contexts for studying PROX1 function in tissue morphogenesis and homeostasis.

  • Co-culture Systems: These allow investigation of PROX1-expressing cells in interaction with other cell types, mimicking in vivo cellular crosstalk.

These technological advances collectively enhance our ability to understand PROX1's multifaceted roles in development, homeostasis, and disease, opening new avenues for therapeutic intervention in PROX1-related pathologies.